Hepatic β-arrestin 2 is essential for maintaining euglycemia

Area of Science:

• * Metabolic disease research
• * Molecular endocrinology
• * Hepatocyte signaling pathways

Background:

• * Increased hepatic glucose production (HGP) is a hallmark of type 2 diabetes.
• * Enhanced signaling via hepatic glucagon receptors (GCGRs) contributes to impaired glucose control.
• * GPCR-associated proteins like β-arrestins play critical roles in regulating receptor signaling.

Purpose of the Study:

• * To investigate the role of β-arrestin 2 in regulating hepatic GCGR signaling and glucose homeostasis.
• * To determine the impact of selective β-arrestin 2 inactivation or overexpression in hepatocytes.
• * To explore therapeutic strategies targeting hepatic β-arrestin 2 for metabolic disorders.

Main Methods:

• * Generation of adult mice with hepatocyte-specific inactivation or overexpression of β-arrestin 2.
• * Assessment of hepatic glucose production, insulin sensitivity, and β-adrenergic signaling.
• * Metabolic phenotyping, including high-fat diet challenges.

Main Results:

• * Hepatocyte-specific β-arrestin 2 deficiency significantly increased hepatic GCGR signaling and worsened glucose homeostasis.
• * Neither β-arrestin 1 deficiency nor altered hepatic insulin or β-adrenergic signaling were observed.
• * Overexpression of β-arrestin 2 in hepatocytes reduced GCGR signaling and protected against high-fat diet-induced metabolic deficits.

Conclusions:

• * Hepatic β-arrestin 2 is a critical negative regulator of glucagon receptor signaling.
• * Targeting hepatic β-arrestin 2 activity offers a potential therapeutic strategy for suppressing HGP in type 2 diabetes.
• * Modulating β-arrestin 2 function represents a promising approach for metabolic disease treatment.